Optimizing Metastatic Risk Prediction in High-Risk Cutaneous Squamous Cell Carcinoma with Gene Expression Profiling

This Blue-Ribbon poster presentation, ranking among the top five abstracts at this year's National Comprehensive Cancer Network (NCCN) Annual Conference, highlighted research in cutaneous squamous cell carcinoma (cSCC) risk evaluation using gene expression profiling.cSCC affects approximately 1.8 million Americans annually; however, identifying high-risk individuals who require more frequent monitoring and other treatment interventions has been challenging.Shlomo A. Koyfman, Director of the Precision Oncology Program and Radiation Oncologist at Cleveland Clinic,